NCT04930653View on ClinicalTrials.gov

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 19, 2022

Primary Completion Date

June 15, 2028

Study Completion Date

June 15, 2028

Conditions
Folliculotropic Mycosis FungoidesPrimary Cutaneous T-Cell Non-Hodgkin LymphomaSezary SyndromeStage IB Mycosis Fungoides and Sezary Syndrome AJCC v8Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8Transformed Mycosis Fungoides
Interventions
PROCEDURE

Extracorporeal Photopheresis

Undergo ECP

BIOLOGICAL

Mogamulizumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (3)

30322

RECRUITING

Winship Cancer Institute of Emory University, Atlanta

85259

RECRUITING

Mayo Clinic, Scottsdale

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER